FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016162191> ?p ?o ?g. }

• W2016162191 endingPage "81" @default.
• W2016162191 startingPage "76" @default.
• W2016162191 abstract "Neoadjuvant administration of chemotherapy provides a unique opportunity to monitor response to treatment in breast cancer and assesses response exactly. Global gene expression profiling by microarrays has been used as a valuable tool for the identification of prognostic and predictive marker genes. Even though this technology is now wide spread and relatively standardized, there are only few data available which compare established parameters with expression values to determine reliability of this method. Therefore we analyzed gene expression data of pretreatment biopsies of breast cancer patients and compared them with the results of the immunohistochemical receptor expression for ER/ PR and Her-2, as well as FISH testing for HER-2 amplification. We analyzed the change of expression of these markers before and after neoadjuvant chemotherapy. Furthermore we evaluated the predictive significance of prognostic gene signatures as described by Sorlie, van't Veer and Ahr for response to neoadjuvant chemotherapy.Pretherapeutic core biopsies were obtained from 70 patients undergoing neoadjuvant TAC chemotherapy within the GEPARTRIO-trial. Samples were characterized according to standard pathology including ER, PR and HER2 IHC and amount of cancer cells. Only biopsies with more than 80 % tumor cells were considered for further examination. RNA was isolated and expression profiling performed using Affymetrix Hg U133 Arrays (22 500 genes). GeneData's Expressionist software was used for bioinformatic analyses.More than two thirds of the biopsies yielded sufficient amounts (> 5 microg) of RNA for expression profiling and high quality data were obtained for 50 samples. Unsupervised clustering broadly revealed a correlation with hormone receptor status. When ER-alpha, PR and HER2 as analyzed by immunohistochemistry were compared to the corresponding mRNA data from gene chips more than 90 % concordance was observed. We could observe a switch of receptor expression for ER, PR or HER-2 from positive to negative and vice versa in 16/35 cases (45.7 %) and 5/22 cases (22.7 %) respectively. The prognostic marker sets of Sorlie, van't Veer and Ahr could not discriminate responders from non-responders in our patient group.Our results demonstrate that reliable expression profiles can be achieved by using limited amounts of tissue obtained during neoadjuvant chemotherapy. Microarray data capture conventional prognostic markers but might contain additional informative gene sets correlated with treatment outcome. Prognostic marker sets are not suitable to predict tumor response in the neoadjuvant setting, suggesting the necessity of class prediction methods to identify marker sets predictive for the type of therapy used." @default.
• W2016162191 created "2016-06-24" @default.
• W2016162191 creator A5011410319 @default.
• W2016162191 creator A5015948613 @default.
• W2016162191 creator A5024589782 @default.
• W2016162191 creator A5026280934 @default.
• W2016162191 creator A5032904905 @default.
• W2016162191 creator A5035387502 @default.
• W2016162191 creator A5038243095 @default.
• W2016162191 creator A5039077602 @default.
• W2016162191 creator A5075403724 @default.
• W2016162191 creator A5083804925 @default.
• W2016162191 creator A5087559224 @default.
• W2016162191 date "2006-04-01" @default.
• W2016162191 modified "2023-10-12" @default.
• W2016162191 title "Gene Expression Profiles of Breast Cancer Obtained from Core Cut Biopsies Before Neoadjuvant Docetaxel, Adriamycin, and Cyclophoshamide Chemotherapy Correlate with Routine Prognostic Markers and Could Be Used to Identify Predictive Signatures" @default.
• W2016162191 cites W2050059533 @default.
• W2016162191 cites W2061423409 @default.
• W2016162191 cites W2091907178 @default.
• W2016162191 cites W2096301110 @default.
• W2016162191 cites W2099721691 @default.
• W2016162191 cites W2109079833 @default.
• W2016162191 cites W2131291033 @default.
• W2016162191 cites W2131994307 @default.
• W2016162191 cites W2140486627 @default.
• W2016162191 cites W2160450758 @default.
• W2016162191 cites W35647293 @default.
• W2016162191 doi "https://doi.org/10.1055/s-2006-921508" @default.
• W2016162191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16673249" @default.
• W2016162191 hasPublicationYear "2006" @default.
• W2016162191 type Work @default.
• W2016162191 sameAs 2016162191 @default.
• W2016162191 citedByCount "24" @default.
• W2016162191 countsByYear W20161621912012 @default.
• W2016162191 countsByYear W20161621912013 @default.
• W2016162191 countsByYear W20161621912014 @default.
• W2016162191 countsByYear W20161621912016 @default.
• W2016162191 countsByYear W20161621912021 @default.
• W2016162191 crossrefType "journal-article" @default.
• W2016162191 hasAuthorship W2016162191A5011410319 @default.
• W2016162191 hasAuthorship W2016162191A5015948613 @default.
• W2016162191 hasAuthorship W2016162191A5024589782 @default.
• W2016162191 hasAuthorship W2016162191A5026280934 @default.
• W2016162191 hasAuthorship W2016162191A5032904905 @default.
• W2016162191 hasAuthorship W2016162191A5035387502 @default.
• W2016162191 hasAuthorship W2016162191A5038243095 @default.
• W2016162191 hasAuthorship W2016162191A5039077602 @default.
• W2016162191 hasAuthorship W2016162191A5075403724 @default.
• W2016162191 hasAuthorship W2016162191A5083804925 @default.
• W2016162191 hasAuthorship W2016162191A5087559224 @default.
• W2016162191 hasConcept C104317684 @default.
• W2016162191 hasConcept C121608353 @default.
• W2016162191 hasConcept C126322002 @default.
• W2016162191 hasConcept C142724271 @default.
• W2016162191 hasConcept C143998085 @default.
• W2016162191 hasConcept C150194340 @default.
• W2016162191 hasConcept C18431079 @default.
• W2016162191 hasConcept C2775934546 @default.
• W2016162191 hasConcept C2776694085 @default.
• W2016162191 hasConcept C2778292576 @default.
• W2016162191 hasConcept C2779733811 @default.
• W2016162191 hasConcept C2781190966 @default.
• W2016162191 hasConcept C502942594 @default.
• W2016162191 hasConcept C530470458 @default.
• W2016162191 hasConcept C55493867 @default.
• W2016162191 hasConcept C71924100 @default.
• W2016162191 hasConcept C86803240 @default.
• W2016162191 hasConceptScore W2016162191C104317684 @default.
• W2016162191 hasConceptScore W2016162191C121608353 @default.
• W2016162191 hasConceptScore W2016162191C126322002 @default.
• W2016162191 hasConceptScore W2016162191C142724271 @default.
• W2016162191 hasConceptScore W2016162191C143998085 @default.
• W2016162191 hasConceptScore W2016162191C150194340 @default.
• W2016162191 hasConceptScore W2016162191C18431079 @default.
• W2016162191 hasConceptScore W2016162191C2775934546 @default.
• W2016162191 hasConceptScore W2016162191C2776694085 @default.
• W2016162191 hasConceptScore W2016162191C2778292576 @default.
• W2016162191 hasConceptScore W2016162191C2779733811 @default.
• W2016162191 hasConceptScore W2016162191C2781190966 @default.
• W2016162191 hasConceptScore W2016162191C502942594 @default.
• W2016162191 hasConceptScore W2016162191C530470458 @default.
• W2016162191 hasConceptScore W2016162191C55493867 @default.
• W2016162191 hasConceptScore W2016162191C71924100 @default.
• W2016162191 hasConceptScore W2016162191C86803240 @default.
• W2016162191 hasIssue "2" @default.
• W2016162191 hasLocation W20161621911 @default.
• W2016162191 hasLocation W20161621912 @default.
• W2016162191 hasOpenAccess W2016162191 @default.
• W2016162191 hasPrimaryLocation W20161621911 @default.
• W2016162191 hasRelatedWork W122589447 @default.
• W2016162191 hasRelatedWork W1255356622 @default.
• W2016162191 hasRelatedWork W1563147852 @default.
• W2016162191 hasRelatedWork W2142354018 @default.
• W2016162191 hasRelatedWork W2156893271 @default.
• W2016162191 hasRelatedWork W2358701816 @default.
• W2016162191 hasRelatedWork W2367105124 @default.
• W2016162191 hasRelatedWork W2370098356 @default.
• W2016162191 hasRelatedWork W2390548009 @default.

• next